[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  14.00 2.58% 556.00 556.00 559.00 559.00 550.00 551.00 217,382 16:35:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 166.7 -138.8 -13.2 - 4,806

Hutchmed (china) Share Discussion Threads

Showing 3226 to 3248 of 3500 messages
Chat Pages: 140  139  138  137  136  135  134  133  132  131  130  129  Older
DateSubjectAuthorDiscuss
06/5/2021
17:53
Not sure how reliable: “There are no current short positions above 0.5% in Hutchison China MediTech Ltd”; Https://www.shortdata.co.uk/company.php?isin=KYG4672N1198
mcmather
06/5/2021
17:20
anybody aware of the level of shorting ?
dbadvn
06/5/2021
16:59
The UT trade - £535.08 - wiped nearly £97m off the market cap...
mcmather
06/5/2021
16:45
I don't think that the management will be too bothered about retail investors (companies in general aren't really fussed about private clients)but they will be concerned about disaffecting recent institutional investors.So,i think things will turn in due course but i confess to having lightened recently out of pure frustration and will need very good cause to buy back.
steeplejack
06/5/2021
16:31
NoS, yes , exactly. He needs to walk the walk now. Asian listing is my decision point.
dbadvn
06/5/2021
16:15
It is getting silly now!
fionascott1234
06/5/2021
16:06
agree DB, i can only hope an Asian listing may do something to help here - I remember you saying CH suggested something will happen to get Investors excited - I will wait to see if anything is forthcoming before making a final decision as to what I will do.
nerdofsteel
06/5/2021
16:02
NoS, I share your frustration , but to be fair Beigene is also down a fair amount ytd. Seems like HM timing is bad yet again....
dbadvn
06/5/2021
15:38
Down 23% YTD for no apparent reason. All we've had in that time is success, NDA's approved, cash rolling in, new Investors (so no dilution) and still the fall continues. If I was GA, Baring Asia or CKHH I'd be questioning what the hell is going on here.
nerdofsteel
06/5/2021
15:36
Unless something changes here in the next couple of months I have decided to call it a day, simply because I am losing money by remaining invested. It could easily be the case that the share price will be the same in another 3 or 4 years, unlikely but possible. Something needs to change soon.
nerdofsteel
06/5/2021
08:41
The volume in London hardly merits the expense of an AIM listing and unless the company engendered real investor interest,it would certainly not be worthwhile stepping up to a full listing despite the potential increase in institutional appeal.The Nasdaq is the critical listing but i note even there,interest seems to be waning.This company may as well go private,do an "Inmarstat".It could take those "privately" courted institutional investors like the Canada pension fund with it into the mists.(Actually,some of those recent purchasers at around 30 bucks must be rueing their timing).
steeplejack
06/5/2021
06:52
I've raised teh subject of moving off AIM directly with the Company many times and they just can't see any reason to do so, or any benefit. Actually I am not sure a Main Listing would change things much. They really need a main listing in Asia IMO. Ditch London and probably ditch NASDAQ in time too. Both have served their purpose.
nerdofsteel
06/5/2021
00:35
This share has become beyond volatile. What other £3 billion company is listed on AIM?
cockneytrader
05/5/2021
21:18
Its all rather strange.We wouldn't want to see a private equity consortium bid approach?
steeplejack
05/5/2021
17:32
I'm a very long term Investor but I am losing patience here. The opportunity cost is simply too high. If I'd put my few hundred £k in FAANG stocks I'd have tripled it in the last 4 years instead of standing still.
nerdofsteel
05/5/2021
16:02
They obviously have other plans for Hutchmed, and I am not sure what those plans are! Three oncology drugs with global potential, with a further pipeline, and no Asia listing or full London listing. Are they trying to keep a lid on the share price? Do they have a big pharma lined up? Or are we all just becoming paranoid?
cockneytrader
05/5/2021
11:56
I would have renamed it something unrelated to medicine or Hutchison. Innovent is a good name, so is Beigene, Incyte, so many great names in use by Biopharma. It sounds to me like they spent 5 minutes to come up with this name, maybe less. CK Hutchison have destroyed Shareholder value here since there absurd botched secondary placing a couple of years back. You would have though a massive sophisticated conglomorate would have had more common sense - they even managed to destroy the value of their OWN INVESTMENT by doing what they did. Botched, mis-timed, moronic, shoddy, lazy, comical, mad, crazy and stupid are just a few words to summarise CKHH's conduct at that time.
nerdofsteel
05/5/2021
10:30
I agree HutchMed is an awful name.When you compare with names like Sanofi or Pfizer,HutchMed sounds like a holiday resort for rabbits.It tells me that Hutchinson hold a substantial stake in this business and we shouldn't forget it.
steeplejack
05/5/2021
10:13
It is now HUTCHMED which is awful IMO. I agree anything like a merger would be after CH has retired. I suspect he wants to be there until they have at least one asset marketed globally (Surufatinib, originally was expected to be Savo).
nerdofsteel
05/5/2021
08:20
NoS Not sure they have fixed the name I think it is Hutchmed (China) CKHH has an ambiguous approach which is to keep the company as an investment and not making it a core part of the group. If listed in HK logically they would call it CK Meditech. I am of the view they will merge it with another China pharma. Probably not while CH is around. He is a founder and won’t surrender his project.
whatja
04/5/2021
17:27
To put out a positive RNS on its first American drug and to see a 7% fall in stock price is bordering on incompetence.
cockneytrader
04/5/2021
16:50
This should not be so difficult to fix. Just find out who is advising Beigene and switch to them + get the US team blitzing the buy side . I think right now they are just relying on contact at conferences rather than pro actively pushing the company other than to possible large one time investors. Certainly the last few days are a big flashing beacon that something is wrong.
dbadvn
04/5/2021
16:24
There isn't any bad news as such rather an inability of the company to manage and generate a full appreciation of its progress against a backcloth of concern about consequences of chinese trade wars.
steeplejack
Chat Pages: 140  139  138  137  136  135  134  133  132  131  130  129  Older
ADVFN Advertorial
Your Recent History
LSE
HCM
Hutchmed (..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210917 23:37:24